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Background and Purpose: Dose escalation in order to improve the biochemical control in prostate cancer requires the ap-
plication of irradiation techniques with high conformality. The dosimetric selectivity of three radiation modalities is compared: 
high-dose-rate brachytherapy (HDR-BT), intensity-modulated radiation radiotherapy (IMRT), and helical tomotherapy (HT).
Patients and Methods: Ten patients with prostate adenocarcinoma treated by a 10-Gy HDR-BT boost after external-beam 
radiotherapy were investigated. For each patient, HDR-BT, IMRT and HT theoretical treatment plans were realized using com-
mon contour sets. A 10-Gy dose was prescribed to the planning target volume (PTV). The PTVs and critical organs’ dose-volume 
histograms obtained were compared using Student’s t-test.
Results: HDR-BT delivers spontaneously higher mean doses to the PTV with smaller cold spots compared to IMRT and HT. 33% of 
the rectal volume received a mean HDR-BT dose of 3.86 ± 0.3 Gy in comparison with a mean IMRT dose of 6.57 ± 0.68 Gy and a 
mean HT dose of 5.58 ± 0.71 Gy (p < 0.0001). HDR-BT also enables to better spare the bladder. The hot spots inside the urethra 
are greater with HDR-BT. The volume of healthy tissue receiving 10% of the prescribed dose is reduced at least by a factor of 8 
with HDR-BT (p < 0.0001).
Conclusion: HDR-BT offers better conformality in comparison with HT and IMRT and reduces the volume of healthy tissue receiving 
a low dose.
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Ein dosimetrischer Vergleich von HDR-Brachytherapie, IMRT und helikaler Tomotherapie bei der Radiotherapie des 
Prostatakarzinoms
Hintergrund und Ziel: Eine Dosiseskalation zur Steigerung der biochemischen Kontrollraten beim Prostatakarzinom erfordert 
die Anwendung von Bestrahlungstechniken, die eine hohe Dosiskonformität ermöglichen. Verglichen wird die dosimetrische 
Selektivität von drei Bestrahlungsmodalitäten: High-Dose-Rate-Brachytherapie (HDR-BT), intensitätsmodulierte Radiotherapie 
(IMRT) und helikale Tomotherapie (HT).
Patienten und Methodik: Zehn Patienten mit einem Adenokarzinom der Prostata, die im Anschluss an eine perkutane Ra-
diotherapie einen Boost von 10 Gy in Form einer HDR-BT erhielten, wurden untersucht. Für jeden dieser Patienten wurden 
Bestrahlungspläne für eine HDR-BT, eine IMRT und eine HT unter Anwendung gemeinsamer Konturierungsverfahren erstellt. Für 
das Planungszielvolumen (PTV) wurden 10 Gy verordnet. Die ermittelten jeweiligen PTV und Dosis-Volumen-Histogramme für die 
kritischen Organe wurden mittels Student-t-Test miteinander verglichen.
Ergebnisse: Die HDR-BT führt zu höheren mittleren Dosen im PTV mit kleineren Cold Spots als die IMRT oder HT. 33% des 
bestrahlten Volumens des Rektums erhielten bei der HDR-BT eine mittlere Dosis von 3,86 ± 0,3 Gy im Vergleich zu 6,57 ± 0,68 
Gy bei der IMRT und 5,58 ± 0,71 Gy bei der HT (p < 0,0001). Die HDR-BT ermöglicht eine bessere Schonung der Harnblase. Die 
Dosisspitzen (Hot Spots) an der Urethra sind jedoch bei der HDR-BT höher. Das Volumen des gesunden Gewebes, das 10% der 
vorgeschriebenen Dosis erhält, wird bei Anwendung der HDR-BT etwa um den Faktor 8 verringert (p < 0,0001).
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Introduction
Many randomized studies have shown that in prostate can-
cer radiotherapy, dose escalation significantly improves the 
rate of biochemical control [24, 27, 28, 39]. Nevertheless, an 
increasing dose to the prostate is associated with a certain 
level of toxicity. Moderate side effects still remain relatively 
frequent even by using a conformal radiation therapy [11, 
38]. Different radiation modalities developed in order to 
improve the conformality of the radiation treatment and to 
decrease the toxicity are under investigation.
High-dose-rate brachytherapy (HDR-BT) is a precise 
hypofractionated radiation treatment whose efficacy is well 
established in prostate cancer [13, 14, 18, 19]. The α/β ratio 
of prostate carcinoma is still being discussed but well known 
to be lower than the typical value of 10 Gy of most other 
solid tumors [4, 9]. So, hypofractionated treatment should be 
able to increase the therapeutic ratio [8, 35]. This hypofrac-
tionation was initially used in HDR-BT in combination with 
external-beam radiation therapy (EBRT) as demonstrated 
in a recent randomized phase III trial [14].
Intensity-modulated radiotherapy (IMRT) is also able 
to safely achieve high dose to the planning target volume 
(PTV) in prostate cancer. Retrospective studies indicate that 
dose distributions of IMRT translate into improved rates of 
disease control and/or lower rates of rectal toxicity [12, 37]. 
A recent study reported acceptable toxicity and favorable 
biochemical outcome provided by ultrahigh-dose (86.4 Gy) 
IMRT for localized prostate cancer [5].
Helical tomotherapy (HT) is an advanced form of con-
tinuous helical IMRT with accurate integrated image-guided 
radiotherapy (IGRT) [34]. This complex rotational method 
of treatment delivery may improve the dose conformity of 
a treatment plan compared with the fixed-beam method of 
IMRT using a limited number of beam directions. First re-
ports encouraged this radiation modality [7, 16, 32].
Improvement of treatment conformality in order to 
spare organs at risk (OARs) sometimes increases the volume 
of healthy tissues at distance of the PTV receiving low radia-
tion doses, with possible higher rates of late side effects such 
as secondary cancers [2, 3].
We therefore decided to compare the dosimetric selec-
tivity of HDR-BT, IMRT and HT on a prostate model with-
out taking the impact of fractionation on tumor control and 
side effects into account.
Patients and Methods
In the beginning of 2007, ten consecutive patients with lo-
calized advance prostate adenocarcinoma treated with a 
10-Gy HDR-BT boost after EBRT were investigated.
HDR-BT was delivered through eight to ten catheters 
placed by the same well-trained radiation oncologist ac-
cording to a method previously reported [23]. Joint slices 
of 5 mm thickness each were obtained and transferred to 
the contouring software platform (Artiview®, Aquilab, 
Lille, France). The clinical target volume (CTV) included 
only the prostate. No further expansion from CTV was 
applied to generate the PTV. The rectum, bladder and 
urethra were contoured entirely. The Brachyvision® (ver-
sion 8, Varian Medical System, Charlottesville, VA, USA) 
treatment-planning system (TPS) was used to calculate the 
treatment for an HDR 192Ir stepping source. At least 95% 
of the PTV had to be covered by the 10-Gy isodose while 
50% could not receive > 150% of the prescribed dose. Dose 
constraints for OARs are represented in Table 1. The dose 
optimization by modeling dwell times was done step by step 
by manually improving a theoretical proposal given at first 
by the TPS.
For this study, we then transferred, via DICOM RT 
link, the computed tomography (CT) scan images and all 
contouring information performed on the Artiview® station 
to the Corvus® (Nomos Corp., Pittsburgh, PA, USA) TPS 
for IMRT and to Hi-Art® (Tomotherapy inc, Madison, WI, 
USA) for HT treatment planning.
Concerning IMRT, a step-and-shoot technique was 
planned with five 6-MV photon beams (0°, 60°, 120°, 240°, 
300°). The PTV was defined as the CTV plus 4 mm in the 
left-right and anterior-posterior axes and 10 mm in the cra-
Schlussfolgerung: Die HDR-BT führt zu einer günstigeren Dosiskonformität im Vergleich zur HT und zur IMRT und reduziert so 
das mit einer niedrigen Dosis belastete Volumen gesunden Gewebes.
Schlüsselwörter: Prostatakarzinom · IMRT · Brachytherapie · Tomotherapie
Table 1. First constraints applied to organs at risk in the different treat-
ment plans for HDR-BT, IMRT and HT dosimetry. HDR-BT: high-dose-rate 
brachytherapy; HT: helical tomotherapy; IMRT: intensity-modulated 
radiotherapy.
Tabelle 1. Dosisbereiche für die Risikoorgane bei den unterschied-
lichen Bestrahlungsplänen für die HDR-BT-, IMRT- und HT-Dosimetrie. 
HDR-BT: High-Dose-Rate-Brachytherapie; HT: helikale Tomotherapie; 
IMRT: intensitätsmodulierte Radiotherapie.
 Tolerated Volume  Minimal  Maximal
 dose (Gy) above (%) dose (Gy) dose (Gy)
Tissues 14 20 5 15
Rectum   5 25 4   7
Urethra 13 20 5 15
Bladder 13 20 5 15
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niocaudal direction. Dose constraints equal to those used 
for HDR-BT were first applied to the PTV and OARs and 
were next modified until the lowest doses to critical organs 
were achieved, while maintaining the initial constraints to 
the PTV.
HT planning was done according to a standardized 
class solution with a field width of 25 mm, a pitch of 0.215, 
and modulation factor of 2. Preliminary constraints for PTV 
and OARs were identical to those introduced in IMRT and 
HDR-BT planning. The dose calculation used a total of 
18.4 full gantry rotations for the dose spread array of the 
incident 6-MV beam. Importance and penalty values were 
adjusted as the dosimetric parameters were modified to ob-
tain the lowest doses to critical organs without decrease of 
the PTV coverage initially planned.
Figure 1. Axial and sagittal views show high conformality of HDR-BT, HT and IMRT. The 10-Gy isodose lines well surround the PTV considered as the 
prostate for HDR-BT and as the prostate with margins taking the prostate motion (blue line) for both other techniques into account.
Abbildung 1. Die Darstellungen in axialer und sagittaler Schnittebene belegen eine hohe Konformalität von HDR-BT, HT und IMRT. Die 10-Gy-Iso-
dose, die das PTV definiert, entspricht dem Prostatavolumen bei der HDR-BT, während für die beiden anderen Bestrahlungstechniken die Bewe-
gungen der Prostata (blaue Linie) mitberücksichtigt wurden.
Figure 2. Axial and sagittal views show volume receiving 5 Gy with HDR-BT, IMRT and HT.
Abbildung 2. Mit 5 Gy belastetes Volumen bei der HDR-BT, IMRT und HT (axiale und sagittale Schnittebene).
Figure 3. Volume of healthy tissues receiving 10% of the prescribed 
dose with the three irradiation techniques.
Abbildung 3. Volumen gesunden Gewebes, das bei den drei Bestrah-
lungstechniken mit 10% der verschriebenen Dosis belastet wird.
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In order to compare the different treatment plan-
ning methods, dose normalization was done to all 
HDR-BT, IMRT and HT plans to obtain a full 
coverage of the PTV with the 95% isodose curve. Then, we 
compared the different PTV and OARs dose-volume histo-
gram parameters of the different treatment options using a 
double-sided paired t-test.
Table 2. Dose received by 95% of planning target volume (PTV), mean 
and minimal doses delivered to the PTV with HDR-BT, IMRT and HT 
modality. HDR-BT: high-dose-rate brachytherapy; HT: helical tomothe-
rapy; IMRT: intensity-modulated radiotherapy.
Tabelle 2. Dosis für 95% des Planungszielvolumens (PTV), mittlere und 
minimale auf das PTV eingestrahlte Dosen für das HDR-BT-, IMRT- und 
HT-Verfahren. HDR-BT: High-Dose-Rate-Brachytherapie; HT: helikale 
Tomotherapie; IMRT: intensitätsmodulierte Radiotherapie.
 Mean for  p-valuea
 10 patients (Gy)
PTV95%  
HDR-BT 10.07 ± 0.02 p = 0.3 HDR-BT vs. IMRT
IMRT 10.01 ± 0.07 p = 0.3 HDR-BT vs. HT
HT 10.00 ± 0 p = 0.6 IMRT vs. HT
PTV mean dose  
HDR-BT 16.23 ± 0.49 p < 0.0001 HDR-BT vs. IMRT
IMRT 10.47 ± 0.18 p < 0.0001 HDR-BT vs. HT
HT 10.41 ± 0.06 p = 0.6 IMRT vs. HT
PTV minimal dose  
HDR-BT   8.97 ± 0.32 p = 0.03 HDR-BT vs. IMRT
IMRT   7.93 ± 1.08 p = 0.05 HDR-BT vs. HT
HT   8.77 ± 0.31 p = 0.04 IMRT vs. HT
adouble-sided paired t-test
Table 3. Maximal doses delivered to the rectum; doses received by 33%, 
20% and 0.5 ml of rectum volume with HDR-BT, IMRT and HT. HDR-
BT: high-dose-rate brachytherapy; HT: helical tomotherapy; IMRT: in-
tensity-modulated radiotherapy.
Tabelle 3. Maximale Dosen am Rektum; Dosen für 33%, 20% und 0,5 ml 
des Rektumvolumens für das HDR-BT-, IMRT- und HT-Verfahren. 
HDR-BT: High-Dose-Rate-Brachytherapie; HT: helikale Tomotherapie; 
IMRT: intensitätsmodulierte Radiotherapie.
 Mean for 10 p-valuea
 patients(Gy)
Maximal rectal dose  
HDR-BT 10.14 ± 0.87 p = 0.3 HDR-BT vs. IMRT
IMRT 10.45 ± 0.22 p = 0.3 HDR-BT vs. HT
HT 10.40 ± 0.24 p = 0.6 IMRT vs. HT
D33% rectum  
HDR-BT   3.86 ± 0.3 p < 0.0001 HDR-BT vs. IMRT
IMRT   6.57 ± 0.68 p < 0.0001 HDR-BT vs. HT
HT   5.58 ± 0.71 p = 0.02 IMRT vs. HT
D20% rectum  
HDR-BT   4.80 ± 0.35 p < 0.0001 HDR-BT vs. IMRT
IMRT   8.08 ± 0.58 p < 0.0001 HDR-BT vs. HT
HT   6.87 ± 0.69 p = 0.004 IMRT vs. HT
D0.5 ml rectum  
HDR-BT   7.99 ± 0.74 p < 0.0001 HDR-BT vs. IMRT
IMRT 10.21 ± 0.38 p < 0.0001 HDR-BT vs. HT
HT 10.04 ± 0.28 p = 0.3 IMRT vs. HT
adouble-sided paired t-test
Table 4. Maximal, mean and minimal doses received by urethra; dose 
received by 20% of urethra volume with HDR-BT, IMRT and HT. HDR-BT: 
high-dose-rate brachytherapy; HT: helical tomotherapy; IMRT: intensi-
ty-modulated radiotherapy.
Tabelle 4. Maximale, mittlere und minimale Dosen an der Urethra; 
Dosis für 20% des Urethravolumens für das HDR-BT-, IMRT- und 
HT-Verfahren.  HDR-BT: High-Dose-Rate-Brachytherapie; HT: helikale 
Tomotherapie; IMRT: intensitätsmodulierte Radiotherapie.
 Mean for 10 p-valuea
 patients (Gy)
Maximal urethral dose  
HDR-BT 13.13 ± 0.74 p < 0.0001 HDR-BT vs. IMRT
IMRT 11.12 ± 0.27 p < 0.0001 HDR-BT vs. HT
HT 10.58 ± 0.13 p = 0.0004 IMRT vs. HT
Mean urethral dose  
HDR-BT 10.52 ± 0.05 p = 0.6 HDR-BT vs. IMRT
IMRT 10.43 ± 0.23 p = 0.6 HDR-BT vs. HT
HT 10.42 ± 0.07 p = 0.89 IMRT vs. HT
Minimal urethral dose  
HDR-BT   5.48 ± 1.56 p = 0.005 HDR-BT vs. IMRT
IMRT   7.90 ± 2.46 p < 0.0001 HDR-BT vs. HT
HT   9.93 ± 0.38 p = 0.027 IMRT vs. HT
D20% urethra  
HDR-BT 10.62 ± 0.41 p = 0.1 HDR-BT vs. IMRT
IMRT 10.46 ± 1.07 p = 0.98 HDR-BT vs. HT
HT 10.49 ± 0.12 p = 0.91 IMRT vs. HT
adouble-sided paired t-test
Table 5. Volume of healthy tissues receiving 10% of the prescribed 
dose. HDR-BT: high-dose-rate brachytherapy; HT: helical tomotherapy; 
IMRT: intensity-modulated radiotherapy.
Tabelle 5. Volumen gesunden Gewebes, das 10% der vorgeschriebenen 
Dosis erhält. HDR-BT: High-Dose-Rate-Brachytherapie; HT: helikale 
 Tomotherapie; IMRT: intensitätsmodulierte Radiotherapie.
 Mean volume receiving  p-valuea
 10% of prescribed 
 dose for 10 patients (ml)
HDR-BT    475.25 ± 87.24 p < 0.0001 HDR-BT vs. IMRT
IMRT 3,899.43 ± 1,183.24 p < 0.0001 HDR-BT vs. HT
HT 5,965.80 ± 1,862.66 p < 0.0001 IMRT vs. HT
adouble-sided paired t-test
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Results
The three treatment plans were able to stick to the dosimet-
ric criteria and the 10-Gy isodose did systematically sur-
round 95% of the PTV while sparing the critical organs. 
Nevertheless, the dose distribution is different with the 
three techniques of irradiation (Figures 1 to 3).
Table 2 presents the doses to the PTV with the three 
different methods. The dose to 95% of the PTV is 10 Gy for 
all the treatments (p ≥ 0.3) which is in accordance with the 
designed methodology. The mean dose to the PTV is signifi-
cantly increased with HDR-BT (16.23 ± 0.49 Gy; p < 0.0001) 
in comparison with the other methods while there is no differ-
ence between IMRT and HT (10.47 ± 0.18 Gy and 10.41 ± 0.06 
Gy, respectively; p = 0.6). Dose distribution inside the PTV is 
more heterogeneous with HDR-BT. Hot spots are observed 
around HDR catheters. Cold spots are slightly less with 
HDR-BT in comparison with HT (8.97 ± 0.32 Gy and 8.77 ± 
0.31 Gy, respectively; p = 0.05) and more important in the 
IMRT planning (7.93 ± 1.08 Gy; p ≤ 0.04). 
Rectal doses are represented in Table 3. The maximal 
dose is similar for the three methods (p ≥ 0.3). The dose deliv-
ered to 0.5 ml of the organ is significantly reduced from 10.21 ± 
0.38 Gy (IMRT) and 10.04 ± 0.28 Gy (HT) to 7.99 ± 0.74 Gy 
with HDR-BT (p < 0.0001). 33% of the rectal volume receives 
a mean dose of 3.86 ± 0.3 Gy with HDR-BT compared to 6.57 ± 
0.68 Gy with IMRT and 5.58 ± 0.71 Gy with HT. The differ-
ence is in favor of HDR-BT (p < 0.001) even if the protection 
rate of the rectum offered by HT is higher than with IMRT 
(p = 0.02).
Likewise, the bladder is better spared with HDR-BT. 
The mean dose to 20% of the OAR is 3.49 ± 0.65 Gy with 
HDR-BT compared to 7.11 ± 1.13 Gy with IMRT and 6.87 ± 
1.09 Gy with HT (p < 0.0001). Urethra irradiation is more 
heterogeneous with HDR-BT with a maximal dose of 13.13 ± 
0.74 Gy and a minimal dose of 5.48 ± 1.56 Gy. For IMRT, 
the maximal and minimal doses are 11.12 ± 0.27 Gy and 
7.9 ± 2.46 Gy; and for HT 10.58 ± 0.13 Gy and 9.93 ± 0.38 
Gy, respectively. The mean dose to the urethra is, however, 
similar for the three approaches (p ≥ 0.6; Table 4).
The volume of distant tissues from the PTV receiv-
ing 10% of the prescribed dose (1 Gy) is 475.25 ± 87.24 
ml, 3,899.43 ± 1,183.24 ml, and 5,965.80 ± 1,862.66 ml 
for HDR-BT, IMRT, and HT, respectively (p < 0.0001; 
Table 5).
Discussion
This study aimed to compare HDR-BT, IMRT and HT as 
a way to deliver a fixed dose to the PTV while best sparing 
the critical organs and healthy distant tissues. Hypofrac-
tionation favored by a low α/β value of prostatic adenocar-
cinoma was initially used in HDR-BT. It is also applicable 
to IMRT and HT but remains under investigation [15, 36]. 
We decided thus to deliver a theoretical normalized dose of 
10 Gy for each of the methods to compare only the dosimet-
ric selectivity of these irradiation techniques without taking 
the impact of hypofractionation into account.
CTV-PTV Expansions
For IMRT and HT, the PTV definition had to consider the 
intrafraction movements of the prostate and the setup un-
certainties before treatment using the most modern IGRT 
techniques [21, 26]. These prostatic intrafraction motions 
required a safety margin of 4 mm from the prostate [1, 22]. 
The longer the treatment duration, the higher the risk of 
displacement, mainly in the craniocaudal direction [17, 20]. 
We therefore decided to fix 4 mm as the internal margin in 
the left-right and anterior-posterior axes and 10 mm in the 
craniocaudal axis. No additional margin was added to take 
setup errors into account assuming that patient position is 
corrected daily applying the most recent IGRT.
Considering HDR-BT, no further expansion from CTV 
was utilized to generate the PTV because movement of the 
implant has no marked influence on dose distribution with 
proper fixation of catheters [25]. Moreover, radiation treat-
ment was performed in the 30 min following the dosimetric 
CT scan while the patient was unable to move.
Dose Distribution Inside the PTV
The goal was not to create a dose painting inside the PTV 
but to create a fall of the dose outside the PTV as sharp as 
possible. HDR-BT allows delivering spontaneously higher 
mean doses to the PTV with smaller cold spots compared to 
IMRT and HT. This higher mean dose in the central parts 
of the prostate is more likely to have clinical consequences 
for tumor control. 
Dose Distribution Inside the OARs
The rectal dose was significantly reduced in the HDR-BT 
approach compared to IMRT and HT approaches. Not 
only maximal doses were decreased but also the mean rec-
tal doses which were recently demonstrated to contribute 
significantly to the toxicity [31]. HT seems to better spare 
the rectum as compared to IMRT. If maximal delivered 
doses are identical with both techniques, doses to 20% and 
33% of the organ are lower with HT compared to IMRT 
(p ≤ 0.02).
The bladder sparing is also greater with HDR-BT in 
comparison with IMRT and HT. The hot spots inside the 
urethra are more marked with HDR-BT. This level of dose 
has, however, not been demonstrated to contribute to in-
creased late toxicity. In phase II studies, Martin et al. and 
Martinez et al. demonstrated the possibility of four 9.5 Gy 
HDR-BT fractions for the treatment of favorable-stage 
prostate cancer (equivalent dose per 2 Gy fraction/EQD2 
95 Gy or 119.5 Gy according the prostate α/β ratio selected 
for the calculation: 3 Gy or 1.5 Gy) [18, 19]. The dose to 
any segment of urethra was limited to ≤ 125% of the pre-
scribed dose (EQD2 of 141 Gy). A recent report shows that 
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doses up to 75.6 Gy and 86.4 Gy are recommended for in-
termediate- and high-risk patients, respectively [39]. If we 
considered a total treatment of HDR-BT with three 10-Gy 
fractions corresponding to EQD2 of 78 Gy or 98.55 Gy (ac-
cording the prostate α/β ratio selected: 3 Gy or 1.5 Gy), the 
maximal dose received by urethra would be an EQD2 of 
127 Gy. Moreover, in our study, the mean urethral dose is 
identical for the three compared methods (p ≥ 0.6).
Risks of Secondary Cancer
Radiation-induced cancers are an uncommon late compli-
cation of radiation therapy [2]. The risk of developing sec-
ond primary cancer in irradiated normal tissues increases as 
radiation dose increases to a maximum at doses around 3–5 
Gy. The cell kill effect becomes dominant at higher doses 
and causes a reduction in survival of transformed cells [29]. 
For low- and intermediate-risk patients, HDR-BT mono-
therapy may be a means of safely delivering higher doses 
with less secondary radiation-induced cancers in com-
parison to IMRT or HT.  HDR-BT as monotherapy is not 
widely established as a standard treatment but is still under 
investigation [6, 13, 18, 19]. Common schedules of HDR 
monotherapy proposed three or four fractions of 9.5–10 Gy 
to the prostate. In this study, the volume of healthy tissue 
receiving 1 Gy is reduced by a factor 8 or 10 when compared 
to IMRT and HT data, respectively (p < 0.0001). Schneider 
et al. showed that dose escalation for prostate radiation 
treatments relates to an increased risk of secondary tumor 
induction [30]. Takam et al. demonstrated that among all 
radiation treatment techniques for prostate cancer, either 
LDR- (low-dose-rate) or HDR-BT offers a smaller risk of 
carcinogenis than treatments involving EBRT techniques 
[33]. These prostate patients are not the most relevant when 
looking at radiation-induced tumors, because the average 
age at treatment of these patients is quite high. Neverthe-
less, taking the risk of secondary cancer into account, HDR 
should be specially recommended to younger patients or 
those with a  life expectancy > 10–15 years. 
Conclusion
HDR-BT remains thus within the radiation therapy tech-
niques offering the highest dosimetric selectivity. The rela-
tively less impressive performances of IMRT and HT are 
partially induced by the need to take a margin for setup 
and organ motion, even with the best IGRT. Irradiation 
offering real tracking properties such as CyberKnife could 
perhaps compete with HDR-BT that is more invasive [10]. 
However, low dose received by healthy tissues at distance 
of the PTV should also be quantified in future CyberKnife 
trials.
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